Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You lost me. What is this referencing?
I think what we’ve found over past couple of years is that the power of social media can create bee swarm effect for retail holders that can much more powerful than Wall Street ever anticipated. GameStop/Bitcoin/AMC are just a few simple examples of this. Large investment funds can’t buy, but small retail holders get in to the rush of excitement (many might be investing for first time) and drive waves of buying/selling on sheer emotions.
Bids starting to lighten up…
No need to uplist at all to be acquired. Uplisting has pros/cons. It opens door to larger investors, funds & indexes, which can help stabilize the share price. However, some of those investment funds are short term holders, which means regular flipping or even hold short. This is when IR is absolutely critical to target the right ownership through sell side analysts, road shows and investor conferences. You want to large target long-term holders.
Would be nice, but think it’s stuck as Elite can’t move forward with it since it has split ownership.
Please don’t be jealous of my corp finance experience. I think the last think I googled was Methotrexeate as it was in the news a few years back, which jogged my memory. I try to keep up on pharma news beyond Elite so I can cast a wider net as a consultant.
I could care less about your Middle East travels. Probably just looking for a new special goat breed. :)
I don’t think he has ever stated a share price goal for a buyout. He has stated he is willing to sell the company (since that is Nasrat’s only realistic way to liquidate ownership).
Large investment firms and funds can’t you can this, but small firms may dabble in ownership. Will be interesting to see if any new ownership filings take place for the quarter.
That’s what I thought. You misinterpreted some basic finance concept. Not a huge surprise for a government worker.
I have worked for so many companies that wouldn’t touch hiring a gov’t worker due to consistent ineptitude. I feel sorry for you dude. Really do.
Your post is so ridiculous. I post on here and finance yahoo under same name. No hidden agenda.
Please show me post # where any insight/response I provided was incorrect. I am more than happy to take ownership of any errors. Would love to see it. I’m guessing it was misread/misinterpreted.
Lol that’s what I thought. You simply stated to ignore R&D. In all acquisitions of which I have been a part, R&D has Never been ignored. Not once.
If there’s a benefit, it’s a synergy, but not excluded when taking into consideration from an acquisition or forward multiple standpoint.
Thanks for admitting you have zero experience in this space. Sit back down and pretend like you do from your computer.
Voice from another country. You must be in ‘Merica country! Lol
Quick question - how many pharma acquisitions have you been close to? Truly.
Last one I was part of was $2.2B acquisition of specialty pharma company from finance integration standpoint. How about you? Just curious.
Agreed, with mid-November Q2 fiscal results release and hopefully generic OxyContin news around time of antimetabolite approval. Will be good next 6 months. I’m eager to hear how R&D pipeline is getting replenished, upcoming filings (excl gen Vyvanse). I expect generic Concerta to be on deck for bioequivalency w/ filing 1H 2024. After this is filed, we don’t have ton of insight into next big opportunities.
If we do in fact get first to file and get past legal hurdles, this stock will absolutely fly.
We all know of the legal and operational issues. You can’t assume we are first in line. Would be great, but no one has that insight at this point and may not for several more months.
Lol amateur
I think today was new money having eyes on Elite where it should be and where it’s going. I expect plenty of volatility, but good days ahead.
Also, don’t expect to be first to file for generic oxy. Would be absolutely awesome. We have no idea. It would be extremely unlikely for Elite to have beaten Intas to the punch after they paved the way winning lawsuits vs Purdue to nullify some parents. Being along the first is still huge.
Look at the date. That was from 3 weeks ago. That’s old news dude.
I have you blocked and just happened to see this. Yes, you are correct in reading a basic P&L. This is why you don’t exclude R&D. You overstate earnings otherwise and everything from earnings to multiples are off. Don’t argue with a financial consultant. You can go back to your government cube now.
And Concerta on deck? Would be nice to see how pipeline is getting replenished with larger drugs.
Looking forward to hearing more on Prasco expectations. I expect that to be a solid stream of rev.
Can we get to 0.15 and get rid of jammy today? Glory is on the horizon.
Getting closer to sayonara threshold…
Actually it’s within 3 business days, as a regulation norm. If we don’t, FDA punted or we received a CRL or request for additional adjustments to be made.
On one of them he stated that margins would be a challenge, but that he believes they will still get to where he would like.
I believe poster is clarifying that dopamine agonist was filed last Dec and due for FDA decision any day now, while slightly larger antimetabolite isn’t due for approval until late Feb. Nothing more, nothing less.
I think you are referring to dopamine agonists coming up this month vs antimetabolite, which isn’t due for another couple months and not the Prasco deal. I could care less about either of these tiny drugs as they aren’t going to add much value to the company, but will take up mfg utilization. With couple big drugs in pipeline, Elite is being faced with question of slimming down pipeline to delay need for separate mfg location or keep smaller drugs expediting need for more mfg space driving more costs and smaller financial return, but helping diversify portfolio little bit at a time.
Just for kicks, you can also layer on Prasco Adderall XR contract mfg deal that starts 1/1/24.
Should be getting news any day now regarding FDA submission for generic Vyvanse.
I see a spread of 0.10/0.104. Been like that most of morning.
Also, R&D is a potential synergy by the acquirer. If they leave Elite as is the company must continue to invest in R&D. It’s seen as an ongoing need. However, the acquirer could stop R&D, combine with theirs, but that simply means the R&D shifts buckets and you drop a few heads. Bottom line, it doesn’t get excluded. Through all acquisitions I have seen and been part of, R&D has never been ignored.
It also is what drives incremental future growth, which is what the PE multiple is all about - future expected growth.
Earnings include R&D. You are just making crap up again dude. You can’t ignore a significant company expense. As of today they are profitable, but barely. They will continue to invest in R&D. Don’t be ignorant to facts. That only gets you gov’t jobs. Oh wait, you worked for the gov’t. Lol
Basic math here has one huge flaw. PE is price to EARNINGS, not revenue. This would assume that Elite incurs no expense whatsoever. Taking an earnings ratio even at a very healthy 30% gives you a drastically lower figure. Last time I checked Elite didn’t get API for free, have a volunteer sales and admin force or get free rent and utilities. Don’t skip over the overhead, variable costs, ongoing R&D & other fixed costs needed to support growth, which will happen.
Completely get it. The glory of being able to mute people on Ihub and ignore their posts.
I really don’t care what IB does. It doesn’t change the financial outlook, cash flow, upcoming deals, FDA approvals or drug launches. If anyone invests what they read on a message board they are taking on some serious risk.
Holy cow! You are right! 0.01% of total outstanding shares sold at a 2% discount to yesterdays closing. Sell everything!!
Please sell all you can. Please.
Looks like you just created a new ID for this post. Kudos for the creativity.